Home Newsfeeds Wolfe Research Downgrades Magellan Midstream to Underperform, Announces $49 Price Target

Wolfe Research Downgrades Magellan Midstream to Underperform, Announces $49 Price Target

Wolfe Research analyst Keith Stanley downgrades Magellan Midstream (NYSE:MMP) from Peer Perform to Underperform and announces $49 price target.

byBenzinga Newsdesk

November 16, 2022

1 minute read

Wolfe Research analyst Keith Stanley downgrades Magellan Midstream (NYSE:MMP) from Peer Perform to Underperform and announces $49 price target.

EXCLUSIVE: Florida On Cusp Of Adult-Use Legalization Cannabis Sales Boom, CEO Tells Benzinga Conference — ‘It’s Going To Be Huge’

By Adam Eckert

April 16, 11:51 AM

'Florida has a million medical card holders, 23 million people living in the state, 130 million visitors a year — it's going to be huge,' says AYR Wellness CEO David Goubert.

MSOS

News

Why Nanobiotix (NBTX) Stock Is Plunging Thursday

By Henry Khederian

November 2, 11:06 AM

Nanobiotix SA - ADR (NASDAQ: NBTX) shares are trading lower by 16.4% to $5.14 Thursday morning after the company priced its global follow-on offering. The offering includes 3,106,907 ADSs in the U.S.

NBTX

$1000 Invested In Synopsys 5 Years Ago Would Be Worth This Much Today

By Benzinga Insights

August 16, 3:43 PM

Synopsys (NASDAQ:SNPS) has outperformed the market over the past 5 years by 25.55% on an annualized basis producing an average annual return of 37.58%. Currently, Synopsys has a market capitalization of $58.79 billion.

SNPS

Immuneering Announces $30M Underwritten Offering Of 2,727,273 Shares Of Common Stock At A Price Of $11/Share

By Happy Mohamed

April 18, 9:28 AM

Immuneering Corporation (NASDAQ:IMRX) ("Immuneering"), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy,

IMRX

Wolfe Research Downgrades Magellan Midstream to Underperform, Announces $49 Price Target

Related Posts

EXCLUSIVE: Florida On Cusp Of Adult-Use Legalization Cannabis Sales Boom, CEO Tells Benzinga Conference — ‘It’s Going To Be Huge’

Why Nanobiotix (NBTX) Stock Is Plunging Thursday

$1000 Invested In Synopsys 5 Years Ago Would Be Worth This Much Today

Immuneering Announces $30M Underwritten Offering Of 2,727,273 Shares Of Common Stock At A Price Of $11/Share